The neuroimmune system is involved in development, normal functioning, aging, and injury
of the central nervous system. Microglia, first described a century ago, are the main …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Transient soluble oligomers of amyloid-β (Aβ) are toxic and accumulate early prior to
insoluble plaque formation and cognitive impairment in Alzheimer's disease (AD). Synthetic …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Microglia activation drives the pro-inflammatory activity in the early stages of Alzheimer's
disease (AD). However, the mechanistic basis is elusive, and the hypothesis of targeting …

Accumulation of misfolded and aggregated forms of tau protein in the brain is a
neuropathological hallmark of tauopathies, such as Alzheimer's disease and frontotemporal …

Amyloid-beta (Aβ) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease
(AD). However, the loss of synapses and dysfunctions of neurotransmission are more …

Inflammation is a pathological hallmark of Alzheimer's disease, and innate immune cells
have been shown to contribute to disease pathogenesis. In two transgenic models of …

Accumulation of amyloid‐β (Aβ) and fibrillary tangles, as well as neuroinflammation and
memory loss, are hallmarks of Alzheimer's disease (AD). After almost 15 years from their …

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …